
Amgen (AMGN) Stock Forecast & Price Target
Amgen (AMGN) Analyst Ratings
Bulls say
Amgen has demonstrated strong revenue growth, with a 40% increase in sales during the third quarter of 2025 compared to the same period in 2024, driven by double-digit growth across 16 of its products, including notable performers such as Repatha and Tezspire. Additionally, the company's investment in research and development is set to enhance its innovative pipeline, with guidance indicating a growth rate exceeding 20% in R&D spending for 2025 compared to the prior year. This combination of robust sales expansion and a commitment to advancing its product offerings supports a positive outlook for Amgen's financial future.
Bears say
Amgen is projected to experience minimal revenue growth of approximately 1% in 2026 compared to 2025, primarily due to significant anticipated sales declines of about 28% for Prolia and 39% for Xgeva. Furthermore, management indicated that growth in research and development spending will be less pronounced than in previous years, which may hinder the company's ability to innovate and offset losses from declining drug sales. These factors contribute to a concerning outlook on Amgen's overall financial health and future revenue streams.
This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.
Amgen (AMGN) Analyst Forecast & Price Prediction
Start investing in Amgen (AMGN)
Order type
Buy in
Order amount
Est. shares
0 shares